Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in ...

Merck MRK announced that the FDA has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and its subcutaneous ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX ...

The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...

The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

Merck & Co Inc. MRK on Wednesday released topline data from the Phase 3 KEYNOTE‑C93 trial of Keytruda (pembrolizumab). Phase ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BERLIN — At a prime-time session on ...